{"id":"W2088614543","doi":"10.1007/s11894-012-0311-3","title":"Novel Targets for Inflammatory Bowel Disease Therapeutics","year":2013,"lang":"en","type":"review","venue":"Current Gastroenterology Reports","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Robarts Clinical Trials","funders":"","keywords":"Ustekinumab; Tofacitinib; Vedolizumab; Medicine; Inflammatory bowel disease; Monoclonal antibody; Ulcerative colitis; Immunology; Crohn's disease; Clinical trial; Monoclonal; Janus kinase; Disease; Infliximab; Antibody; Internal medicine; Cytokine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008068402,0.001179671,0.002001799,0.001660148,0.000281287,0.001171408,0.001041865,0.001274858,0.004219988],"category_scores_gemma":[0.0007579149,0.0003571078,0.0005824118,0.001268848,0.0006786223,0.001521477,0.0008354249,0.00367029,0.00247455],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006275611,"about_ca_system_score_gemma":0.0007547968,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000475036,"about_ca_topic_score_gemma":0.001421542,"domain_scores_codex":[0.9997781,0.0000390338,0.000027155,0.00003400107,0.00008516727,0.00003652628],"domain_scores_gemma":[0.9997252,0.000122449,0.00003736761,0.00001121211,0.00006797867,0.00003581162],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001921202,0.0001475663,0.0001316839,0.006791458,0.00008547418,0.0003158209,0.00003208866,0.0004850711,0.004339775,0.004261888,0.04924928,0.9339676],"study_design_scores_gemma":[0.00008317519,0.0001421168,0.0004678814,0.001535329,0.0001324118,0.0008209825,0.00003671792,0.0001766566,0.001039069,0.002534488,0.9930097,0.00002143629],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001607223,0.9968935,0.0003593906,0.0005567857,0.000605404,0.000008786648,0.00002850269,0.00002068774,0.001366189],"genre_scores_gemma":[0.001194357,0.9957681,0.000594795,0.0005843752,0.0004430772,0.00001701554,0.00006574849,0.000004322668,0.001328331],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004219988,"threshold_uncertainty_score":0.01411724,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03379967257626593,"score_gpt":0.3142006582837941,"score_spread":0.2804009857075281,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}